Christopher R. Bishop, Ph.D. - Publications

Affiliations: 
Binghamton University, Vestal, NY, United States 

78 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Centner A, Del Priore I, Chambers N, Cohen SR, Terry ML, Coyle M, Glinski J, Stoll AC, Patterson JR, Kemp CJ, Miller KM, Kubik M, Kuhn N, Luk KC, Sortwell CE, ... Bishop C, et al. Deficits in basal and evoked striatal dopamine release following alpha-synuclein preformed fibril injection: An in vivo microdialysis study. The European Journal of Neuroscience. PMID 38356120 DOI: 10.1111/ejn.16275  0.758
2023 Kasanga EA, Soto I, Centner A, McManus R, Shifflet MK, Navarrete W, Han Y, Lisk J, Wheeler K, Mhatre-Winters I, Richardson JR, Bishop C, Nejtek VA, Salvatore MF. Moderate intensity aerobic exercise in 6-OHDA-lesioned rats alleviates established motor deficits and reduces neurofilament light and glial fibrillary acidic protein serum levels without increased striatal dopamine or tyrosine hydroxylase protein. Biorxiv : the Preprint Server For Biology. PMID 37502851 DOI: 10.1101/2023.07.11.548638  0.323
2023 Conti Mazza MM, Centner A, Werner DF, Bishop C. Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats. Brain Research. 148381. PMID 37127174 DOI: 10.1016/j.brainres.2023.148381  0.456
2023 Budrow C, Elder K, Coyle M, Centner A, Lipari N, Cohen S, Glinski J, Kinzonzi N, Wheelis E, McManus G, Manfredsson F, Bishop C. Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia. Cells. 12. PMID 36980178 DOI: 10.3390/cells12060837  0.746
2022 Lipari N, Centner A, Glinski J, Cohen S, Manfredsson FP, Bishop C. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease. Neurobiology of Disease. 105965. PMID 36526089 DOI: 10.1016/j.nbd.2022.105965  0.795
2022 Moreno E, Casajuana-Martin N, Coyle M, Campos BC, Galaj E, Del Torrent CL, Seyedian A, Rea W, Cai NS, Bonifazi A, Florán B, Xi ZX, Guitart X, Casadó V, Newman AH, ... Bishop C, et al. Pharmacological targeting of G protein-coupled receptor heteromers. Pharmacological Research. 106476. PMID 36182040 DOI: 10.1016/j.phrs.2022.106476  0.32
2022 Salvatore MF, Kasanga EA, Kelley DP, Venable KE, McInnis TR, Cantu MA, Terrebonne J, Lanza K, Meadows SM, Centner A, Bishop C, Ingram DK. Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake. Geroscience. PMID 35635679 DOI: 10.1007/s11357-022-00583-7  0.315
2022 Cohen SR, Terry ML, Coyle M, Wheelis E, Centner A, Smith S, Glinski J, Lipari N, Budrow C, Manfredsson FP, Bishop C. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats. Pharmacology, Biochemistry, and Behavior. 217: 173393. PMID 35513119 DOI: 10.1016/j.pbb.2022.173393  0.801
2022 Smith S, Sergio J, Coyle M, Elder K, Centner A, Cohen S, Terry M, Lipari N, Glinski J, Wheelis E, Budrow C, Bishop C. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. Psychopharmacology. PMID 35275226 DOI: 10.1007/s00213-022-06078-9  0.789
2021 Lanza K, Bishop C. Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia. Biomedicines. 9. PMID 33808538 DOI: 10.3390/biomedicines9030314  0.437
2021 Chambers NE, Coyle M, Sergio J, Lanza K, Saito C, Topping B, Clark SD, Bishop C. Effects of Pedunculopontine Nucleus Cholinergic Lesion on Gait and Dyskinesia in Hemiparkinsonian Rats. The European Journal of Neuroscience. PMID 33426708 DOI: 10.1111/ejn.15106  0.432
2020 Lanza K, Centner A, Coyle M, Del Priore I, Manfredsson FP, Bishop C. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia. Experimental Neurology. 336: 113534. PMID 33249031 DOI: 10.1016/j.expneurol.2020.113534  0.404
2020 Kiessling CY, Lanza K, Feinberg E, Bishop C. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats. Neuropharmacology. 108138. PMID 32492451 DOI: 10.1016/J.Neuropharm.2020.108138  0.773
2020 Steece-Collier K, Collier TJ, Lipton JW, Stancati JA, Winn ME, Cole-Strauss A, Sellnow R, Conti MM, Mercado NM, Nillni EA, Sortwell CE, Manfredsson FP, Bishop C. Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in fisher 344 vs. Lewis hemiparkinsonian rats. Experimental Neurology. 113327. PMID 32387398 DOI: 10.1016/J.Expneurol.2020.113327  0.397
2019 Chambers NE, Lanza K, Bishop C. Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson's Disease. Frontiers in Pharmacology. 10: 1494. PMID 32009944 DOI: 10.3389/Fphar.2019.01494  0.381
2019 Bishop C. Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 34: 1758-1760. PMID 31845761 DOI: 10.1002/Mds.27900  0.459
2019 Lanza K, Chemakin K, Lefkowitz S, Saito C, Chambers N, Bishop C. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. Psychopharmacology. PMID 31435690 DOI: 10.1007/S00213-019-05353-6  0.512
2019 Lanza K, Perkins AE, Deak T, Bishop C. Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat. Neurobiology of Aging. 81: 190-199. PMID 31306813 DOI: 10.1016/J.Neurobiolaging.2019.05.019  0.444
2019 Chambers NE, Meadows SM, Taylor A, Sheena E, Lanza K, Conti MM, Bishop C. Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat. Neuroscience. PMID 31029732 DOI: 10.1016/J.Neuroscience.2019.04.008  0.562
2019 Guitart X, Moreno E, Rea W, Sánchez-Soto M, Cai NS, Quiroz C, Kumar V, Bourque L, Cortés A, Canela EI, Bishop C, Newman AH, Casadó V, Ferré S. Biased G Protein-Independent Signaling of Dopamine D-D Receptor Heteromers in the Nucleus Accumbens. Molecular Neurobiology. PMID 30919214 DOI: 10.1007/S12035-019-1564-8  0.399
2019 Sellnow RC, Newman JH, Chambers N, West AR, Steece-Collier K, Sandoval IM, Benskey MJ, Bishop C, Manfredsson FP. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. Acta Neuropathologica Communications. 7: 8. PMID 30646956 DOI: 10.1186/S40478-018-0653-7  0.541
2018 Meadows SM, Conti MM, Gross L, Chambers NE, Avnor Y, Ostock CY, Lanza K, Bishop C. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats. Movement Disorders : Official Journal of the Movement Disorder Society. 33: 1740-1749. PMID 30485908 DOI: 10.1002/Mds.100  0.53
2018 Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferré S, Bishop C. Behavioral and cellular dopamine D and D receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology. PMID 29936243 DOI: 10.1016/J.Neuropharm.2018.06.024  0.575
2018 Conti MM, Chambers N, Bishop C. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia. Neuroscience and Biobehavioral Reviews. PMID 29782883 DOI: 10.1016/J.Neubiorev.2018.05.021  0.526
2018 Ostock CY, Bhide N, Goldenberg AA, George JA, Bishop C. Striatal norepinephrine efflux in l-DOPA-induced dyskinesia. Neurochemistry International. PMID 29371053 DOI: 10.1016/J.Neuint.2018.01.010  0.58
2018 Lanza K, Bishop C. Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 29305656 DOI: 10.1007/S00702-017-1837-1  0.512
2017 Lindenbach D, Das B, Conti MM, Meadows SM, Dutta AK, Bishop C. D-512, a novel dopamine D2 / D3 receptor agonist, demonstrates superior anti-parkinsonian efficacy over ropinirole in parkinsonian rats. British Journal of Pharmacology. PMID 28667675 DOI: 10.1111/Bph.13937  0.4
2017 Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, Salvatore MF. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28631864 DOI: 10.1002/Mds.27077  0.497
2017 Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C. Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. Experimental Neurology. 292: 168-178. PMID 28342749 DOI: 10.1016/J.Expneurol.2017.03.013  0.464
2016 Lindenbach D, Conti MM, Ostock CY, George JA, Goldenberg AA, Melikhov-Sosin M, Nuss EE, Bishop C. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 9873-87. PMID 27656025 DOI: 10.1523/Jneurosci.1318-16.2016  0.526
2016 Conti MM, Meadows SM, Melikhov-Sosin M, Lindenbach D, Hallmark J, Werner DF, Bishop C. Monoamine transporter contributions to L-DOPA effects in hemi-parkinsonian rats. Neuropharmacology. PMID 27452719 DOI: 10.1016/J.Neuropharm.2016.07.025  0.554
2016 Conti MM, Goldenberg AA, Kuberka A, Mohamed M, Eissa S, Lindenbach D, Bishop C. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. Pharmacology, Biochemistry, and Behavior. 142: 64-71. PMID 26791104 DOI: 10.1016/J.Pbb.2016.01.004  0.567
2015 Lindenbach D, Conti MM, Ostock CY, Dupre KB, Bishop C. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia. Neuroscience. PMID 26363150 DOI: 10.1016/J.Neuroscience.2015.09.018  0.797
2015 Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. Journal of Neurochemistry. 134: 222-32. PMID 25866285 DOI: 10.1111/Jnc.13125  0.607
2015 Ostock CY, Hallmark J, Palumbo N, Bhide N, Conti M, George JA, Bishop C. Modulation of l-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus. Neuropharmacology. 95: 215-25. PMID 25817388 DOI: 10.1016/J.Neuropharm.2015.03.008  0.539
2015 Lindenbach D, Palumbo N, Ostock CY, Vilceus N, Conti MM, Bishop C. Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. British Journal of Pharmacology. 172: 119-30. PMID 25175895 DOI: 10.1111/Bph.12894  0.487
2014 Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Bishop C. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Behavioural Brain Research. 270: 75-85. PMID 24837745 DOI: 10.1016/J.Bbr.2014.05.009  0.571
2014 Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology. 77: 1-8. PMID 24067924 DOI: 10.1016/J.Neuropharm.2013.09.017  0.597
2014 Ostock CY, Bishop C. The role of the noradrenergic system and its receptors in levodopa-induced dyskinesia Levodopa-Induced Dyskinesia in Parkinson's Disease. 265-283. DOI: 10.1007/978-1-4471-6503-3_15  0.309
2013 Lindenbach D, Bishop C. Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease. Neuroscience and Biobehavioral Reviews. 37: 2737-50. PMID 24113323 DOI: 10.1016/J.Neubiorev.2013.09.008  0.385
2013 Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease. Brain Research. 1537: 327-39. PMID 24060645 DOI: 10.1016/J.Brainres.2013.09.020  0.846
2013 Dupre KB, Ostock CY, George JA, Eskow Jaunarajs KL, Hueston CM, Bishop C. Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. Acs Chemical Neuroscience. 4: 747-60. PMID 23496922 DOI: 10.1021/Cn300234Z  0.822
2013 Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Bishop C, Berger SP, Paquette MA. The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology. 227: 533-44. PMID 23389756 DOI: 10.1007/S00213-013-3001-4  0.586
2012 Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European Journal of Neuroscience. 36: 2839-48. PMID 22762478 DOI: 10.1111/J.1460-9568.2012.08202.X  0.577
2012 Eskow Jaunarajs KL, George JA, Bishop C. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience. 218: 243-56. PMID 22659568 DOI: 10.1016/J.Neuroscience.2012.05.052  0.573
2012 Barnum CJ, Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Tignor S, Klioueva A, Walters H, Bishop C. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacology, Biochemistry, and Behavior. 100: 607-15. PMID 21978941 DOI: 10.1016/J.Pbb.2011.09.009  0.557
2011 Ostock CY, Dupre KB, Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, Bishop C. Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology. 61: 753-60. PMID 21635907 DOI: 10.1016/J.Neuropharm.2011.05.021  0.799
2011 Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. The Journal of Pharmacology and Experimental Therapeutics. 337: 755-65. PMID 21402691 DOI: 10.1124/Jpet.111.179416  0.835
2011 Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Experimental Neurology. 229: 288-99. PMID 21352823 DOI: 10.1016/J.Expneurol.2011.02.012  0.818
2011 Kuhn DM, Sykes CE, Geddes TJ, Jaunarajs KL, Bishop C. Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. Journal of Neurochemistry. 116: 426-37. PMID 21105877 DOI: 10.1111/J.1471-4159.2010.07123.X  0.771
2011 Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neuroscience and Biobehavioral Reviews. 35: 556-64. PMID 20615430 DOI: 10.1016/J.Neubiorev.2010.06.007  0.446
2010 Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, Bishop C. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behavioural Pharmacology. 21: 627-37. PMID 20838211 DOI: 10.1097/Fbp.0B013E32833E7E80  0.819
2009 Jaunarajs KL, Dupre KB, Steiniger A, Klioueva A, Moore A, Kelly C, Bishop C. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport. 20: 1265-9. PMID 19633584 DOI: 10.1097/Wnr.0B013E3283300Fd7  0.811
2009 Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse (New York, N.Y.). 63: 610-20. PMID 19309758 DOI: 10.1002/Syn.20630  0.829
2009 Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. Journal of Neuroscience Research. 87: 1645-58. PMID 19115412 DOI: 10.1002/Jnr.21978  0.843
2008 Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology. 55: 1321-8. PMID 18824001 DOI: 10.1016/J.Neuropharm.2008.08.031  0.841
2008 Barnum CJ, Eskow KL, Dupre K, Blandino P, Deak T, Bishop C. Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: Role for interleukin-1β Neuroscience. 156: 30-41. PMID 18687386 DOI: 10.1016/J.Neuroscience.2008.07.016  0.824
2008 Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology. 199: 99-108. PMID 18545986 DOI: 10.1007/S00213-008-1135-6  0.832
2007 Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacology, Biochemistry, and Behavior. 87: 306-14. PMID 17553556 DOI: 10.1016/J.Pbb.2007.05.002  0.572
2007 Dupre KB, Eskow KL, Negron G, Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Research. 1158: 135-43. PMID 17553470 DOI: 10.1016/J.Brainres.2007.05.005  0.82
2006 Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. The European Journal of Neuroscience. 23: 2669-76. PMID 16817869 DOI: 10.1111/J.1460-9568.2006.04790.X  0.571
2006 Taylor JL, Bishop C, Ullrich T, Rice KC, Walker PD. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology. 50: 761-8. PMID 16434065 DOI: 10.1016/J.Neuropharm.2005.12.004  0.562
2005 Taylor JL, Bishop C, Walker PD. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacology, Biochemistry, and Behavior. 81: 887-93. PMID 16023708 DOI: 10.1016/J.Pbb.2005.06.013  0.527
2005 Bishop C, Daut GS, Walker PD. Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology. 49: 350-8. PMID 15993442 DOI: 10.1016/J.Neuropharm.2005.03.008  0.547
2005 Krolewski DM, Bishop C, Walker PD. Intrastriatal dopamine D1 receptor agonist-mediated motor behavior is reduced by local neurokinin 1 receptor antagonism. Synapse (New York, N.Y.). 57: 1-7. PMID 15858838 DOI: 10.1002/Syn.20148  0.513
2004 Bishop C, Walker PD. Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. Brain Research. 1023: 126-33. PMID 15364027 DOI: 10.1016/J.Brainres.2004.07.039  0.49
2004 Bishop C, Tessmer JL, Ullrich T, Rice KC, Walker PD. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. The Journal of Pharmacology and Experimental Therapeutics. 310: 687-94. PMID 15044557 DOI: 10.1124/Jpet.104.066365  0.5
2004 Bishop C, Parker GC, Coscina DV. Systemic nicotine alters whole-body fat utilization in female rats. Physiology & Behavior. 80: 563-7. PMID 14741242 DOI: 10.1016/J.Physbeh.2003.10.011  0.599
2003 Bishop C, Walker PD. Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience. 121: 649-57. PMID 14568025 DOI: 10.1016/S0306-4522(03)00516-5  0.52
2003 Bishop C, Kamdar DP, Walker PD. Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. Synapse (New York, N.Y.). 50: 164-70. PMID 12923819 DOI: 10.1002/Syn.10253  0.523
2003 Bishop C, Parker GC, Coscina DV. Nicotine and its withdrawal modify dorsal raphe 8-hydroxy-2-(di-n-propylamino) tetralin feeding. Pharmacology, Biochemistry, and Behavior. 74: 961-7. PMID 12667911 DOI: 10.1016/S0091-3057(03)00026-1  0.636
2002 Bishop C, Parker GC, Coscina DV. Nicotine and its withdrawal alter feeding induced by paraventricular hypothalamic injections of neuropeptide Y in Sprague-Dawley rats. Psychopharmacology. 162: 265-72. PMID 12122484 DOI: 10.1007/S00213-002-1101-7  0.623
2002 Parker GC, Bishop C, Coscina DV. Estrous cycle and food availability affect feeding induced by amygdala 5-HT receptor blockade. Pharmacology, Biochemistry, and Behavior. 71: 701-7. PMID 11888561 DOI: 10.1016/S0091-3057(01)00668-2  0.627
2001 Parker GC, McKee ME, Bishop C, Coscina DV. Whole-body metabolism varies across the estrous cycle in Sprague-Dawley rats. Physiology & Behavior. 74: 399-403. PMID 11714505 DOI: 10.1016/S0031-9384(01)00599-6  0.604
2001 Currie PJ, Coscina DV, Bishop C, Coiro CD, Koob GF, Rivier J, Vale W. Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Research. 916: 222-8. PMID 11597609 DOI: 10.1016/S0006-8993(01)02851-7  0.684
2000 Coscina DV, Currie PJ, Bishop C, Parker GC, Rollins BL, King BM. Posterodorsal amygdala lesions reduce feeding stimulated by 8-OH-DPAT. Brain Research. 883: 243-9. PMID 11074055 DOI: 10.1016/S0006-8993(00)02918-8  0.725
2000 Bishop C, Currie PJ, Coscina DV. Effects of three neurochemical stimuli on delayed feeding and energy metabolism. Brain Research. 865: 139-47. PMID 10814743 DOI: 10.1016/S0006-8993(00)02310-6  0.682
1987 Phillips A, Hahn DW, Capetola RJ, Bishop C, McGuire JL. Anaphylactoid and anti-ovulatory activities of LHRH antagonists in rats. Life Sciences. 41: 2017-22. PMID 3312903 DOI: 10.1016/0024-3205(87)90475-9  0.303
Show low-probability matches.